OCT-guided therapy
Through short-term monitoring and data processing of the OCT imaging system, the problem of early detection of macular degeneration diseases is solved, timely monitoring and treatment adjustment of retinal status is achieved, and vision loss is delayed.
Patent Information
- Application Number
- CN202380034116.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-13
- Filing Date
- 2023-04-11
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively detect and monitor retinal changes in the early stages of macular degeneration, resulting in delayed treatment and thus affecting visual retention.
Using an OCT imaging-based system, the state of the retina is monitored in a short period of time, and the communication unit, processor and storage device are used to generate and process OCT image data, measure fluid volume changes, and notify medical professionals based on thresholds to adjust treatment plans in a timely manner. .
Early detection and monitoring of retinal diseases is achieved, allowing more frequent treatment adjustments, delaying vision loss, and improving the accuracy and timeliness of treatment.
Smart Images

Figure CN119031877A_ABST
Abstract
Description
Cross-references to related applications
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 330,666, filed on April 13, 2022, the entire contents of which are incorporated herein by reference in their entirety for all purposes. Background Art
[0002] Macular degeneration is the leading cause of vision loss in the United States. In macular degeneration, the central part of the retina, also called the macula, deteriorates. When healthy, the macula collects and sends highly detailed images to the brain via the optic nerve. In the early stages, macular degeneration usually does not significantly affect vision. If macular degeneration progresses beyond the early stages, vision will become choppy and / or blurry. If macular degeneration continues to progress to the advanced stages, central vision may be lost.
[0003] Although macular degeneration is currently considered incurable, treatments do exist that can slow the progression of the disease in order to prevent severe vision loss. Treatment options include: injections of anti-angiogenic drugs into the eye, laser therapy to destroy actively growing abnormal blood vessel(s), and photodynamic laser therapy that uses light-sensitive drugs to destroy abnormal blood vessel(s). Early detection of macular degeneration is critical to preventing late-stage progression of macular degeneration before treatment can be used to inhibit disease progression.
[0004] Early detection of macular degeneration can be accomplished using an appropriate retinal imaging system. For example, optical coherence tomography (OCT) is a non-invasive imaging technique that relies on low-coherence interferometry that can be used to generate cross-sectional images of the macula. A cross-sectional view of the macula shows whether the macular layer is deformed, and can be used to monitor whether the macular layer deformation increases or decreases relative to an earlier cross-sectional image to assess the impact of treatments for macular degeneration. Summary of the invention
[0005] A simplified overview of some embodiments of the present invention is presented below to provide a basic understanding of the present invention. Summary of the present invention is not a broad overview of the present invention. It is not intended to identify the key / determining elements of the present invention or to describe the scope of the present invention. Its sole purpose is to present some embodiments of the present invention in a simplified form as a preface to the specific embodiments presented later.
[0006] In many embodiments, short-term monitoring (e.g., daily) of the subject's retinal disease state using optical coherence tomography (OCT) imaging of the subject's retina is used to provide valuable information to the treating physician. In many embodiments, the OCT image data of the retina is generated by an affordable OCT-based ophthalmic imaging device that can be used by the subject at home on a short-term basis to monitor the state of the subject's retinal disease. Short-term monitoring can achieve more accurate tracking of the state of the subject's retinal disease and develop treatment methods based on the day-to-day changes in the subject's retinal disease state, rather than the hit-or-miss treatment methods that can be used when checking the subject's retinal disease state at a typical current interval (e.g., once a month, once every 5 weeks, once every 6 weeks, etc.). In many embodiments, short-term monitoring enables improved scheduling of the application of treatments for the subject's retinal disease (e.g., injecting a therapeutic compound into the subject's eye). In some embodiments, short-term monitoring can be used to formulate a customized treatment plan for the subject based on the observed progression of the subject's retinal disease and / or the observed response of the subject's retinal disease to one or more previous treatment applications.
[0007] Therefore, in one aspect, a system for tracking the status of a retinal disease in a subject's eye includes a communication unit, at least one processor, and a tangible storage device storing non-transient instructions. The communication unit is configured to receive optical coherence tomography (OCT) image data of the subject's retina for each of a series of OCT imaging sessions of the retina with a suitable imaging frequency (e.g., at least once every two weeks, at least once a week, at least once every three days, at least once every two days, at least once a day). The non-transient instructions are executable by at least one processor to cause at least one processor to process the OCT image data of the retina to determine a series of measured extent values. Each of the measured extent values in the series of measured extent values indicates a corresponding extent of the retinal disease. The instructions may further cause the processor to generate an output indicating a series of measured extent values.
[0008] In many embodiments of the system, a series of OCT imaging sessions of the retina are performed during the treatment interval of the retinal disease. For example, in some retinal diseases, the treatment interval (e.g., the time span between injections of the therapeutic compound to the subject's eye) can be about one month or longer (e.g., 4 weeks, 5 weeks, 6 weeks, 7 weeks or longer). Performing a series of OCT imaging sessions during the treatment interval provides visibility related to the extent of the retinal disease at the time point between treatments. Therefore, the extent of the retinal disease between treatment applications can be measured and tracked, thereby providing the treating medical professional with feedback on any regression and / or progress in the extent of the retinal disease between treatment applications. A series of OCT imaging can be performed over any suitable time span and at any suitable frequency. For example, a series of OCT imaging sessions can be performed over at least one month or longer to cover at least one time span between treatment applications. A series of OCT imaging sessions may have the following imaging frequencies: at least once every two weeks, at least once a week, at least once every three days, or at least once a day.
[0009] In some embodiments of the system, the measured extent values indicate an amount of fluid within the retina. For example, at least one measured extent value in a series of measured extent values may indicate a length of a volume of fluid within the retina detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate a depth of a volume of fluid within the retina detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate a volume of a volume of fluid within the retina detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate a length of a volume of subretinal fluid detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate a depth of a volume of subretinal fluid detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate a volume of a volume of subretinal fluid detected via a series of OCT imaging sessions of the retina.
[0010] In many embodiments, the system is configured to generate and send a notification to a designated treatment professional of the subject in response to the subject's retinal disease progressing to or exceeding a selected threshold value, so as to enable the application of a treatment for the subject's retinal disease to be scheduled based on the observed progression of the subject's retinal disease. For example, in some embodiments, the non-transient instructions further cause the at least one processor to compare at least one of the series of measured degree values with a corresponding threshold degree value, and in response to at least one of the series of measured degree values being equal to or exceeding the corresponding threshold degree value, transmit a communication to the treatment professional when at least one of the series of measured degree values exceeds the corresponding threshold degree value. In some embodiments, the non-transient instructions further cause the at least one processor to compare at least one of the series of measured degree values with a corresponding threshold degree value, and in response to at least one of the series of measured degree values being equal to or exceeding the corresponding threshold degree value, cause remote treatment of the retinal disease via operation of the implanted pump to inject a therapeutic compound into the eye.
[0011] In many embodiments of the system, the non-transitory instructions further cause the at least one processor to transmit at least one measured degree value of the series of one or more degree values to a treating professional to enable tracking of the progression of the retinal disease by the treating professional. In some embodiments, the non-transitory instructions further cause the at least one processor to transmit a graph of at least one measured degree value of the series of one or more degree values to the treating professional. In some embodiments, the non-transitory instructions further cause the at least one processor to display at least one measured degree value of the series of one or more degree values to the treating professional.
[0012] In some embodiments, the system is configured to determine a parameter describing the extent of retinal disease in a subject between treatment applications. For example, in some embodiments, the system is configured to measure the extent of intraretinal fluid within the retina. In some embodiments, the non-transient instructions further cause at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is subsequent to the first treatment for the retinal disease and is performed consecutively with the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) calculate at least one fluid presence interval within the treatment interval, during which at least one fluid presence interval, a volume of intraretinal fluid is detected in each of a series of OCT imaging sessions of the retina completed during the fluid presence interval. The non-transient instructions may further cause at least one processor to calculate a fluid absence interval within the treatment interval, during which a volume of intraretinal fluid is not detected via each of a series of OCT imaging sessions of the retina completed during the treatment interval. In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is subsequent to and consecutive to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) calculate a fluid regression interval within the treatment interval, during which a volume of intraretinal fluid detected in a series of OCT imaging sessions of the retina decreases in volume during the fluid regression interval. In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is subsequent to and consecutive to the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) calculate a fluid gain interval within the treatment interval, during which a volume of intraretinal fluid detected in a series of OCT imaging sessions of the retina increases in volume during the fluid gain interval.In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is subsequent to the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) determine a maximum thickness of the volume of intraretinal fluid detected via a series of OCT imaging sessions of the retina during the treatment interval. In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for the first treatment for the retinal disease, (b) store a second treatment date for the second treatment for the retinal disease, wherein the second treatment for the retinal disease is subsequent to the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) determine a maximum volume of the volume of intraretinal fluid detected via a series of OCT imaging sessions of the retina during the treatment interval.
[0013] In some embodiments, the system is configured to measure the extent of subretinal fluid within the retina. For example, in some embodiments, the non-transitory instructions further cause at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively with the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) calculate at least one fluid-presence interval within the treatment interval, during which the volume of subretinal fluid is detected in each of a series of OCT imaging sessions of the retina completed during the fluid-presence interval. In some embodiments, the non-transitory instructions further cause at least one processor to calculate a fluid-absence interval within the treatment interval, during which the volume of subretinal fluid is not detected via each of a series of OCT imaging sessions of the retina completed during the treatment interval. In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is subsequent to the first treatment for the retinal disease and is performed consecutively with the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) calculate a fluid regression interval within the treatment interval, during which a volume of subretinal fluid detected in a series of OCT imaging sessions of the retina decreases in volume during the fluid regression interval. In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is subsequent to the first treatment for the retinal disease and is performed consecutively with the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) calculate a fluid gain interval within the treatment interval, during which a volume of subretinal fluid detected in a series of OCT imaging sessions of the retina increases in volume during the fluid gain interval.In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for a first treatment for a retinal disease, (b) store a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is subsequent to and consecutive to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) determine a maximum thickness of the subretinal fluid volume detected via a series of OCT imaging sessions of the retina during the treatment interval. In some embodiments, the non-transitory instructions further cause the at least one processor to: (a) store a first treatment date for the first treatment for the retinal disease, (b) store a second treatment date for the second treatment for the retinal disease, wherein the second treatment for the retinal disease is subsequent to and consecutive to the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) determine a maximum volume of the subretinal fluid volume detected via a series of OCT imaging sessions of the retina during the treatment interval.
[0014] In some embodiments, the system is configured to monitor the subject's compliance with a specified schedule for imaging the subject's retina. For example, in some embodiments of the system, the OCT imaging data includes imaging date data indicating a date on which each of a series of OCT imaging sessions of the retina occurred, and the non-transitory instructions further cause the at least one processor to: (a) process the imaging date data to monitor the subject's non-compliance with the specified schedule for performing the series of OCT imaging sessions of the retina, and (b) in response to detecting the subject's non-compliance with the specified schedule for performing the series of OCT imaging sessions of the retina, transmit a reminder to the subject to comply with the specified schedule for performing the series of OCT imaging sessions of the retina.
[0015] In some embodiments, the system is configured to assess the severity of a retinal disease in a subject.For example, in some embodiments, the non-transitory instructions further cause the at least one processor to generate a severity score indicating the severity of the retinal disease based on the OCT imaging data.
[0016] In some embodiments, the system is configured to generate a recommendation for treatment of a retinal disease in a subject. For example, in some embodiments, the non-transient instructions further cause at least one processor to generate a recommendation for treatment of a retinal disease based on the OCT imaging data. The recommendation for treatment may include a recommended date for injecting the therapeutic compound into the eye. The recommendation for treatment may include a recommended volume of the therapeutic compound for injection into the eye and / or a recommended composition of the therapeutic compound.
[0017] The system can be configured to track the progression of any suitable retinal disease. For example, in some embodiments of the system, retinal diseases that can be tracked can include pigment epithelial detachment, drusen, chorioretinal eye diseases such as AMD, ocular histoplasmosis, myopia, central serous retinopathy, central serous choroidopathy, glaucoma, diabetic retinopathy, retinitis pigmentosa, optic neuritis, epiretinal membranes, vascular abnormalities and / or occlusions, choroidal dystrophy, retinal dystrophy, macular holes, or choroidal or retinal degeneration.
[0018] In another aspect, a method for tracking the progression of a retinal disease in a subject includes receiving, by a computing system, optical coherence tomography (OCT) image data of the subject's retina for each of a series of OCT imaging sessions of the retina having a suitable imaging frequency (e.g., at least once every two weeks, at least once a week, at least once every three days, at least once every two days, at least once a day). The OCT image data of the retina is processed by the computer system to determine a series of measured extent values, wherein each of the series of measured extent values indicates a corresponding extent of the retinal disease. Output indicating the series of measured extent values is output by the computer system.
[0019] In many embodiments of the method, a series of OCT imaging sessions of the retina are performed during the treatment interval of the retinal disease. For example, in some retinal diseases, the treatment interval (e.g., the time span between injections of the therapeutic compound to the subject's eye) can be about one month or longer (e.g., 4 weeks, 5 weeks, 6 weeks, 7 weeks or longer). Performing a series of OCT imaging sessions during the treatment interval provides visibility related to the extent of the retinal disease at the time point between treatments. Therefore, the retinal disease response between treatment applications can be measured and tracked, thereby providing the treating medical professional with feedback on any regression and / or progression of the extent of the retinal disease between treatment applications. A series of OCT imaging sessions can be performed within any suitable time span and at any suitable frequency. For example, a series of OCT imaging sessions can be performed over at least one month or longer to cover at least one time span between treatment applications. A series of OCT imaging sessions can have the following imaging frequencies: at least once every two weeks, at least once a week, at least once every three days, or at least once a day.
[0020] In some embodiments of the method, the measured extent values indicate the amount of fluid within the retina. For example, at least one measured extent value in a series of measured extent values may indicate the length of the volume of fluid within the retina detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate the depth of the volume of fluid within the retina detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate the volume of the volume of fluid within the retina detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate the length of the volume of subretinal fluid detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate the depth of the volume of subretinal fluid detected via a series of OCT imaging sessions of the retina. At least one measured extent value in a series of measured extent values may indicate the volume of the subretinal fluid volume detected via a series of OCT imaging sessions of the retina.
[0021] In many embodiments, the method includes generating a notification and sending the notification to a designated treatment professional of the subject in response to the subject's retinal disease progressing to or exceeding a selected threshold value so as to enable scheduling of application of treatment for the subject's retinal disease based on the observed progression of the subject's retinal disease. For example, in some embodiments, the method includes comparing, by a computer system, at least one of the series of measured degree values with a corresponding threshold degree value, and in response to at least one of the series of measured degree values being equal to or exceeding the corresponding threshold degree value, transmitting a communication by the computer system to the treatment professional when at least one of the series of measured degree values exceeds the corresponding threshold degree value. In some embodiments, the method further includes comparing, by a computer system, at least one of the series of measured degree values with a corresponding threshold degree value, and in response to at least one of the series of measured degree values being equal to or exceeding the corresponding threshold degree value, causing, by the computer system, remote treatment of the retinal disease via operation of an implanted pump to inject a therapeutic compound into the eye.
[0022] In many embodiments, the method includes: transmitting, by the computer system, at least one of the one or more degree values of the series of measurements to a treating professional to enable the treating professional to track the progression of the retinal disease. In some embodiments, the method includes: transmitting, by the computer system, a graph of at least one of the one or more degree values of the series of measurements to the treating professional. In some embodiments, the method includes: displaying, by the computer system, at least one of the one or more degree values of the series of measurements to the treating professional.
[0023] In some embodiments, the method includes: determining, by a computer system, a parameter describing the extent of retinal disease in a subject between treatment applications. For example, in some embodiments, the method includes: measuring and tracking the extent of intraretinal fluid within the retina. For example, in some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by a computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively with the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) calculating, by the computer system, at least one intraretinal fluid presence interval within the treatment interval, during which at least one intraretinal fluid presence interval, a volume of intraretinal fluid is detected in each of a series of OCT imaging sessions of the retina completed during the intraretinal fluid presence interval. The method may include: calculating, by a computer system, a fluid absence interval within the treatment interval, during which a volume of intraretinal fluid is not detected in each of a series of OCT imaging sessions of the retina completed during the fluid absence interval. In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by the computer system, a second treatment date for a second treatment for the retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) calculating, by the computer system, an intraretinal fluid regression interval within the treatment interval, during which intraretinal fluid volume detected in a series of OCT imaging sessions of the retina decreases in volume during the intraretinal fluid regression interval. In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by a computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) calculating, by the computer system, an intraretinal fluid increase interval within the treatment interval, during which intraretinal fluid volume detected in a series of OCT imaging sessions of the retina increases in volume during the intraretinal fluid increase interval.In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by a computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) determining, by the computer system, a maximum thickness of the volume of intraretinal fluid detected via a series of OCT imaging sessions of the retina during the treatment interval. In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by a computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) determining, by the computer system, a maximum volume of the volume of intraretinal fluid detected via a series of OCT imaging sessions of the retina during the treatment interval.
[0024] In some embodiments, the method includes measuring the extent of subretinal fluid within the retina. For example, in some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by a computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively with the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) calculating, by the computer system, at least one subretinal fluid presence interval within the treatment interval, during which at least one subretinal fluid presence interval, a subretinal fluid volume is detected in each of a series of OCT imaging sessions of the retina completed during the subretinal fluid presence interval. In some embodiments, the method includes: calculating, by the computer system, a subretinal fluid absence interval within the treatment interval, during which a subretinal fluid volume is not detected in each of a series of OCT imaging sessions of the retina completed during the subretinal fluid absence interval. In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by the computer system, a second treatment date for a second treatment for the retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) calculating, by the computer system, a subretinal fluid regression interval within the treatment interval, during which subretinal fluid volume detected in a series of OCT imaging sessions of the retina decreases in volume during the subretinal fluid regression interval. In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by the computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) calculating, by the computer system, a subretinal fluid increase interval within the treatment interval, during which subretinal fluid volume detected in a series of OCT imaging sessions of the retina increases in volume during the subretinal fluid increase interval.In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by a computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein a treatment interval extends from the first treatment date to the second treatment date, and (c) determining, by the computer system, a maximum thickness of the subretinal fluid volume detected via a series of OCT imaging sessions of the retina during the treatment interval. In some embodiments, the method includes: (a) storing, by a computer system, a first treatment date for a first treatment for a retinal disease, (b) storing, by a computer system, a second treatment date for a second treatment for a retinal disease, wherein the second treatment for the retinal disease is performed after the first treatment for the retinal disease and is performed consecutively to the first treatment for the retinal disease, and wherein the treatment interval extends from the first treatment date to the second treatment date, and (c) determining, by the computer system, a maximum volume of the subretinal fluid volume detected via a series of OCT imaging sessions of the retina during the treatment interval.
[0025] In some embodiments, the method includes: monitoring, by a computer system, the subject's compliance with a specified schedule for performing imaging of the subject's retina. For example, in some embodiments of the method, the OCT imaging data includes imaging date data indicating a date on which each of a series of OCT imaging sessions of the retina occurred, and the method includes: (a) processing, by a computer system, the imaging date data to monitor the subject's non-compliance with the specified schedule for performing the series of OCT imaging sessions of the retina, and (b) in response to detecting the subject's non-compliance with the specified schedule for performing the series of OCT imaging sessions of the retina, transmitting, by the computer system, a reminder to the subject to comply with the specified schedule for performing the series of OCT imaging sessions of the retina.
[0026] In some embodiments, the method includes assessing, by a computer system, the severity of a retinal disease in a subject. For example, in some embodiments, the method includes generating, by a computer system, a severity score indicating the severity of a retinal disease based on OCT imaging data.
[0027] In some embodiments, the method includes: generating, by a computer system, a recommendation for treatment of a retinal disease in a subject. For example, in some embodiments, the method includes generating, by a computer system, a recommendation for treatment of a retinal disease based on OCT imaging data. The recommendation for treatment may include a recommended date for injecting a therapeutic compound into the eye. The recommendation for treatment may include a recommended volume of a therapeutic compound for injection into the eye and / or a recommended composition of a therapeutic compound for injection into the eye.
[0028] The method may include tracking the status of any suitable retinal disease by a computer system. For example, retinal diseases that may be tracked via the method include pigment epithelial detachment, drusen, chorioretinal eye diseases such as AMD, ocular histoplasmosis, myopia, central serous retinopathy, central serous choroidopathy, glaucoma, diabetic retinopathy, retinitis pigmentosa, optic neuritis, epiretinal membranes, vascular abnormalities and / or occlusions, choroidal dystrophy, retinal dystrophy, macular holes, or choroidal or retinal degeneration.
[0029] In another aspect, a system for managing treatment of a retinal disease of an eye of a subject includes a communication unit, at least one processor, and a tangible storage device. The communication unit is configured to receive optical coherence tomography (OCT) image data of the retina for each of a series of OCT imaging sessions of the retina of the subject. The tangible storage device stores non-transitory instructions executable by at least one processor to cause the at least one processor to: (a) process the OCT image data of the retina to determine a series of measured retinal fluid level values; and (b) generate a treatment recommendation for the subject by executing a treatment algorithm using input based on the series of measured retinal fluid level values.
[0030] The treatment algorithm can be formulated using any suitable method. For example, the treatment algorithm can be a machine learning algorithm that is trained using training data including multiple series of retinal fluid level values. In some embodiments, the training data further includes treatment application data associated with the multiple series of retinal fluid level values.
[0031] The treatment recommendation can be any suitable treatment recommendation for a retinal eye disease. For example, the treatment recommendation can include a recommended date for a therapeutic injection into the subject's eye, a recommended compound for the therapeutic injection, and / or a recommended volume of the recommended compound for the therapeutic injection.
[0032] In another aspect, a system for predicting the progression of a retinal disease in an eye of a subject includes a communication unit, at least one processor, and a tangible storage device. The communication unit is configured to receive optical coherence tomography (OCT) image data of the retina for each of a series of OCT imaging sessions of the retina of the subject. The tangible storage device stores non-transitory instructions executable by at least one processor to cause the at least one processor to: (a) process the OCT image data of the retina to determine a series of measured retinal fluid level values; and (b) generate a prediction of the progression of the retinal disease by executing a prediction algorithm using an input based on the series of measured retinal fluid level values.
[0033] The prediction algorithm can be formulated using any suitable method. For example, the prediction algorithm can be a machine learning algorithm that is trained using training data including multiple series of retinal fluid level values. In some embodiments, the training data further includes therapeutic application data associated with the multiple series of retinal fluid level values.
[0034] The prediction algorithm can be configured to generate any suitable prediction of the progression of a retinal eye disease. For example, the prediction of the progression of a retinal disease can include a predicted treatment response of a subject to a treatment for the retinal disease. In some embodiments, the treatment for the retinal disease includes injecting a therapeutic compound into the subject's eye. In some embodiments, the prediction of the progression of a retinal disease includes a predicted progression of a series of increasing retinal fluid level values.
[0035] In another aspect, a system for classifying a retinal disease of an eye of a subject includes a communication unit, at least one processor, and a tangible storage device. The communication unit is configured to receive optical coherence tomography (OCT) image data of the retina for each of a series of OCT imaging sessions of the retina of the subject. The tangible storage device stores non-transient instructions that are executable by at least one processor to cause the at least one processor to: (a) process the OCT image data of the retina to determine a series of measured retinal fluid level values; and (b) determine a classification of the retinal disease of the eye of the subject by executing a classification algorithm using an input based on the series of measured retinal fluid level values. In many embodiments, the classification is selected from a plurality of predetermined classifications.
[0036] The classification algorithm can be formulated using any suitable method. For example, the classification algorithm can be a machine learning algorithm that is trained using training data including multiple series of retinal fluid level values. In some embodiments, the training data further includes therapeutic application data associated with the multiple series of retinal fluid level values.
[0037] The classification algorithm can be configured to generate any suitable classification of the retinal disease of the subject's eye. For example, the classification of the retinal disease of the subject's eye indicates the severity of the retinal disease of the subject's eye. In some embodiments, the classification of the retinal disease of the subject's eye indicates the effectiveness of a treatment for the retinal disease of the subject's eye.
[0038] For a more complete understanding of the nature and advantages of the present invention, reference should be made to the ensuing detailed description and accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] Figure 1is a simplified schematic diagram of a method of monitoring a subject for retinal disease, according to an embodiment.
[0040] Figure 2 According to the embodiment, Figure 1 A simplified schematic diagram of the method of the method.
[0041] Figure 3 An OCT-generated image of a retina with intraretinal fluid is shown, where the image is generated via a remote OCT imaging device in accordance with an embodiment.
[0042] Figure 4 An OCT-generated image of a retina with subretinal fluid is shown, where the image is generated via a remote OCT imaging device in accordance with an embodiment.
[0043] Figure 5 Shows that you can Figure 2 An example report generated by the method for use by a treating medical professional.
[0044] Figure 6 Shows that you can Figure 2 Another example report generated in the method for use by a treating medical professional.
[0045] Figure 7 Shows that you can Figure 2 Another example report generated in the method for use by a treating medical professional.
[0046] Figure 8 Shown are graphs of intraretinal fluid volume and subretinal fluid volume over a span of dates between treatments in accordance with an embodiment.
[0047] Fig. 9 Shows that you can Figure 2 A diagram of a method to track and identify some different rates of progression of retinal fluid accumulation.
[0048] Fig.10 Shows that you can Figure 2 A method of tracking and identifying a number of different types of responders to a treatment application.
[0049] Fig.11 Shows that you can Figure 2 A method for tracking and identifying non-responders to a treatment application.
[0050] Fig. 12A and Fig. 12B Graphs of example retinal fluid volume trajectories associated with prescheduled retreatment intervals are shown.
[0051] FIG. 13A to FIG. 13F Graphs of example retinal fluid volume trajectories and associated customized retreatment intervals are shown.
[0052] Fig.14 The diagram illustrates a method for predictive modeling of treatment outcomes using periodic OCT-generated retinal images, according to an embodiment.
[0053] Fig.15 A method flow chart of a method for generating treatment-related parameters using periodic OCT-generated retinal images according to an embodiment is shown.
[0054] Fig.16 The figure illustrates example retinal fluid volume trajectory segments, which are automatically identified in an embodiment.
[0055] Fig.17A and Fig. 17B Plots of example retinal fluid volume trajectories with automatically identified segments are shown.
[0056] Fig.18A An example segmented retinal fluid volume trajectory is shown, including a first response segment and a second response segment.
[0057] Fig.18B Shown in Fig.18A Retinal fluid volume trajectory of the OCT retinal images obtained during the first response segmentation.
[0058] Fig.18C Shown in Fig.18A Figure 2. Retinal fluid volume trajectory of the OCT retinal images obtained during the second response segmentation.
[0059] Fig.19A A graph of an example retinal fluid volume trajectory of a portion of a patient's retina is shown and includes a first activation segment, a first response segment, a second activation segment, and a second response segment.
[0060] Fig.19B Shown in Fig.19A Fluid volume map of the OCT retinal image acquired during the first activated segmentation.
[0061] Fig.19C Shown in Fig.19A Fluid volume map of OCT retinal images acquired during the second activation segmentation.
[0062] Fig. 20A A graph showing an example retinal fluid volume trajectory for a portion of the retina of another patient is shown.
[0063] Fig. 20B Shown in Fig. 20A Fluid volume map of the OCT retinal image acquired during the first activated segmentation.
[0064] Fig. 20C Shown in Fig. 20A Fluid volume maps of OCT retinal images acquired during first response segmentation.
[0065] Fig.20D Shown in Fig. 20A Fluid volume map of OCT retinal images acquired during the second activation segmentation.
[0066] Fig.20E Shown in Fig. 20A Fluid volume maps of OCT retinal images acquired during the second response segmentation.
[0067] Fig.20F Shows Fig. 20A Graph of percent fluid reduction in treatment response for the first response segment.
[0068] Figure 20G Shows Fig. 20A Figure 2 shows a graph of percent fluid reduction in response to treatment for the second response segment.
[0069] Fig. 20H Shows Fig. 20A Figure 3. First half-life fluid volume plot of the retinal fluid volume trajectory.
[0070] Fig.20I Shows Fig. 20A Figure 2. Second half-life fluid volume plot of the retinal fluid volume trajectory.
[0071] Fig.21A A graph showing an example retinal fluid volume trajectory for a portion of the retina of another patient is shown.
[0072] Fig.21B Shown in Fig.21A Fluid volume map of the OCT retinal image acquired during the first activated segmentation.
[0073] Fig. 21C Shown in Fig.21A Fluid volume maps of OCT retinal images acquired during first response segmentation.
[0074] Fig.21D Shown in Fig.21A Fluid volume map of OCT retinal images acquired during the second activation segmentation.
[0075] Fig.21E Shown in Fig.21AFluid volume maps of OCT retinal images acquired during the second response segmentation.
[0076] Fig.21F Shows Fig.21A Graph of percent fluid reduction in treatment response for the first response segment.
[0077] Figure 21G Shows Fig.21A Figure 2 shows a graph of percent fluid reduction in response to treatment for the second response segment.
[0078] Fig.21H Shows Fig.21A Figure 3. First half-life fluid volume plot of the retinal fluid volume trajectory.
[0079] Fig.21I Shows Fig.21A Figure 2. Second half-life fluid volume plot of the retinal fluid volume trajectory.
[0080] Fig.22A A graph showing an example retinal fluid volume trajectory for a portion of the retina of another patient is shown.
[0081] Fig. 22B Shown in Fig.22A Final fluid volume map of the OCT retinal images acquired during the first response segmentation.
[0082] Fig. 22C Shows Fig.22A Graph of percent fluid reduction in treatment response for the first response segment.
[0083] Fig.22D Shown in Fig.22A Final fluid volume map of the OCT retinal images acquired during the second response segmentation.
[0084] Fig.22E Shows Fig.22A Figure 2 shows a graph of percent fluid reduction in response to treatment for the second response segment.
[0085] Fig.22F Shown in Fig.22A Final fluid volume map of the OCT retinal image acquired during the third response segmentation.
[0086] Figure 22G Shows Fig.22A Graph of percent fluid reduction in treatment response for the third response segment.
[0087] Fig.23A , Fig. 23B and Fig.23C Fluid volume maps for the patient's three activation segments are shown.
[0088] Fig.24A , Fig. 24B , Fig.24C , Fig.24D and Fig.24E The diagram shows activation in different locations within the patient's retina.
[0089] Fig.25 An example graphical user interface of a system for use with home OCT retinal imaging to manage retinal disease in a patient is illustrated in accordance with an embodiment. DETAILED DESCRIPTION
[0090] In the following description, various embodiments of the present invention will be described. For the purpose of explanation, specific configurations and details are set forth in order to provide a thorough understanding of the embodiments. However, it will also be apparent to those skilled in the art that the present invention can be practiced without these specific details. In addition, in order not to confuse the described embodiments, well-known features may be omitted or simplified.
[0091] introduction
[0092] Many subjects with retinal diseases are treated with intraocular injections according to general guidelines based on average subjects. The progression of retinal disease in any particular subject may be different from that of the average subject. In addition, the response of a particular subject to treatment may be different from that of the average subject. Therefore, there is a strong clinical need to monitor the progression of retinal disease in certain subjects on a short-interval basis so that the subjects can receive treatment based on their own disease progression. Ophthalmology clinics typically use ophthalmic imaging equipment using optical coherence tomography (OCT) imaging to image the subject's retina to assess the health of the subject's retina and / or to assess the status of the subject's retinal disease. However, having to go to an ophthalmology clinic may prevent the completion of repeated imaging of the subject's retina at sufficiently short intervals suitable for adequately monitoring the status of the subject's retinal disease. Retinal diseases that may be suitable for management via repeated OCT imaging on a short-interval basis include, but are not limited to, chorioretinal eye diseases such as AMD, ocular histoplasmosis, myopia, central serous retinopathy, central serous choroidopathy, glaucoma, diabetic retinopathy, retinitis pigmentosa, optic neuritis, epiretinal membranes, vascular abnormalities and / or occlusions, choroidal dystrophy, retinal dystrophy, macular holes, or choroidal or retinal degenerations.
[0093] In many embodiments described herein, a subject uses an economical OCT-based ophthalmic imaging device during a series of OCT imaging sessions performed on a short-interval basis to generate a corresponding series of OCT images of the subject's retina, thereby monitoring the state of the subject's retinal disease. As used herein, "short-interval basis" refers to any suitable interval between OCT imaging sessions in a series of OCT imaging sessions, so as to generate one or more OCT images of the subject during a period between treatments of the subject's retinal disease (e.g., injections of therapeutic compounds into the subject's eyes), which are typically spaced at least four weeks apart. Each subject may have a specific maximum interval between generating OCT images of the subject's retina sufficient to adequately monitor the state of the subject's retinal disease. The maximum interval between generating OCT images of the subject's retina for a particular subject may be selected by the subject's treating medical professional. The maximum interval for generating OCT images of the subject's retina for a particular subject may include, but is not limited to, at least once a day, at least once every two days, at least once every three days, at least once a week, and at least once every two weeks. Short-interval basal OCT imaging of the subject's retina can enable improved monitoring of the state of the subject's retinal disease and enable development of a customized treatment regimen for the subject. In some embodiments, short-interval basal OCT imaging of the subject's retina is used to determine when to induce remote treatment by injecting a therapeutic compound into the subject's eye via a remote pump fluidically coupled to the subject's eye.
[0094] Any suitable parameter or suitable combination of parameters can be used to track the progression of a retinal disease in a subject. For example, in some embodiments described herein, the volume of fluid in the subject's retina (e.g., intraretinal fluid volume, subretinal fluid volume) is measured via short-interval basal OCT imaging of the subject's retina using an OCT-based ophthalmic imaging device used remotely (e.g., at home) by the subject.
[0095] In some embodiments, the amount of fluid in the subject's retina is plotted to graphically illustrate how the amount of fluid in the subject's retina changes on a selected periodic basis (e.g., day by day). The resulting graphical representation can be used to illustrate the effect of the application of a suitable therapeutic compound and / or treatment on the state of a subject's retinal disease over time. The resulting graphical representation can also be used to illustrate the difference in the effect of the application of a suitable therapeutic compound and / or treatment on the state of a subject's retinal disease over time.
[0096] Any suitable biomarker indicating the state of a subject's retinal disease, as well as biomarker progression and degree of remission can be assessed using the systems and / or methods described herein. Suitable biomarkers include, but are not limited to, intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachment (PED), drusen, and macular holes.
[0097] In some embodiments, a data set indicating the extent of suitable biomarkers is evaluated by an algorithm that generates a recommendation regarding the next therapeutic application for treating a subject's retinal disease. The generated recommendation may include, for example, a recommended date for the next visit to a clinic for evaluation and / or treatment of the subject's retinal disease, a recommended date for the next injection of a therapeutic compound into the subject's eye to treat the subject's retinal disease, and / or a recommended type of therapeutic compound (e.g., injection amount, drug combination).
[0098] Retinal disease tracking based on remote retinal imaging OCT system
[0099] Referring now to the drawings, wherein like reference numerals represent like parts throughout the several views, Figure 1 A simplified schematic diagram of a method 10 for monitoring a retinal disease in a subject according to an embodiment is shown. The method 10 involves generating an output to a treating professional of the subject for use in managing treatment of the retinal disease in the subject based on short-interval basal OCT imaging of the subject's retina. The short-interval basal OCT imaging of the subject's retina generates a series of OCT images of the subject's retina. The method 10 can be used to remotely monitor the status of the retinal disease in the subject over any suitable time period (such as between clinical visits and / or administration of treatment for the retinal disease in the subject).
[0100] In act 12, a first OCT image (OCT image (1)) of the subject's retina is generated. The first OCT image can be generated after the monitoring period begins, such as after administration of a treatment (e.g., injection of a therapeutic compound into the subject's eye) or at a suitable interval (such as those described herein) after clinical-based OCT imaging of the subject's retina.
[0101] In act 14, the first OCT image is processed to measure one or more biomarkers indicative of the state of the subject's retinal disease. Any suitable number and / or type of biomarkers may be measured, including but not limited to those described herein.
[0102] In act 16, the biomarker(s) measured in the first OCT image are compared to the selected limit(s) of the biomarker(s). If the biomarker(s) measured in the first OCT image exceeds the selected limit(s) of the biomarker(s), an alarm is generated and output to mark the occurrence of the exceedance. In many embodiments, the alarm is output to a medical professional treating the retinal disease of the subject.
[0103] In act 18, the counter is set to 2 for generating and processing a second OCT image of the subject's retina in method 10. To generate and process subsequent OCT images of the subject's retina in method 10, the counter is incremented in act 30. Acts 20 to 26 are repeated for each value of the counter.
[0104] In act 20, an OCT image (counts) of the subject's retina is generated. The OCT image (counts) may be generated at a suitable interval (such as those described herein) after the OCT image (counts-1) is generated.
[0105] In act 22, the OCT images (counts) are processed to measure one or more biomarkers indicative of the state of the subject's retinal disease. In many embodiments, the measured biomarker(s) are the same as the biomarker(s) measured in each of the series of OCT images measured in method 10.
[0106] In act 24, the biomarker(s) measured in the OCT image (counts) are compared to selected limit(s) for the biomarker(s). If the biomarker(s) measured in the OCT image (counts) exceed the selected limit(s) for the biomarker(s), an alarm is generated and output to mark the occurrence of the exceedance. In many embodiments, the alarm is output to a medical professional treating the subject's retinal disease.
[0107] In act 26, one or more parameters are calculated that indicate a change in the amplitude of the (multiple) biomarkers from OCT image (counts-1) to OCT image (counts). The calculated (multiple) parameters reflect whether the state of the subject's retinal disease has improved from OCT image (counts-1) to OCT image (counts) (e.g., as indicated by a decrease in the amplitude of the (multiple) biomarkers), or whether the state of the subject's retinal disease has worsened from OCT image (counts-1) to OCT image (counts) (e.g., as indicated by an increase in the amplitude of the (multiple) biomarkers). The calculated one or more parameters may include any suitable parameters calculated from the measured (multiple) biomarkers, including but not limited to those described herein.
[0108] In act 28, if the OCT image (count) is the last in the specified series of interim OCT images of the subject's retina, method 10 continues to act 32. If the OCT image (count) is not the last in the specified series of interim OCT images of the subject's retina, method 10 continues to act 30, in which a counter is incremented for generating and processing the next OCT image via completion of repeating acts 20 through 28 for the next OCT image in the series of OCT images of the subject's retina. Acts 20 through 28 are repeated until the last OCT image in the series of OCT images is generated and processed. When the last OCT image in the series of OCT images has been generated and processed, method 10 continues to act 32.
[0109] In act 32, the values of the one or more biomarkers and / or the calculated parameters indicating the change of the (multiple) biomarkers between the pair of OCT image sequences are output. The values of the one or more biomarkers and / or the calculated parameters can be output to any suitable recipient, including but not limited to a medical professional involved in the management and / or treatment of a retinal disease in a subject.
[0110] In act 34, a recommendation for treatment of the retinal disease in the subject is formulated based on the values of the one or more biomarkers and / or the calculated parameters. The recommendation may include, but is not limited to: (a) a recommended date for injecting the therapeutic compound into the eye, (b) a recommended volume of the therapeutic compound to be injected into the eye, and / or (c) a recommended composition of the therapeutic compound to be injected into the eye.
[0111] Figure 2 A simplified schematic diagram of a method 40 for completing method 10 is shown in accordance with an embodiment. The method 40 includes short-interval-based repeated generation 42 of OCT image data of a subject's retina by an OCT-based ophthalmic imaging device 44. In many embodiments, the generation 42 of the OCT image data can be repeated at any suitable interval as described herein. Any suitable OCT-based ophthalmic imaging device can be used as the imaging device 44, including but not limited to an affordable subject-operable OCT imaging device that can be used remotely by the subject (e.g., at home).
[0112] The OCT image data for each imaging session of the subject's retina is transmitted 46 to a retinal disease management system 48. In many embodiments, the OCT image data is transmitted separately for each imaging session of the subject's retina to the retinal disease management system 48. For example, in some cases, the subject is instructed to use the imaging device daily, and the resulting OCT image data of the subject's retina is transmitted to the retinal disease management system 48 for each corresponding daily imaging session.
[0113] In many embodiments, the retinal disease management system 48 is web-based and configured to manage various aspects of tracking the status of a retinal disease for each of a plurality of subjects. Various aspects of tracking the status of a retinal disease for each of a plurality of subjects manageable via the retinal disease management system 48 include, but are not limited to: 1) providing an instance of the imaging device 44 to each of one or more subjects monitored via the retinal disease management system 48, 2) acquiring and storing identification and treatment-related data for each of the subjects monitored via the retinal disease management system 48, 3) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 4) monitoring compliance of each of the subjects monitored by the retinal disease management system 48 with a periodic imaging interval requirement (e.g., a daily imaging requirement), 5) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 6) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 7) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 8) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 9) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 10) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 11) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 12) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 13) providing subject education related to the use of the imaging device 44 and / or treatment of the subject's retinal disease, 14) providing subject education related to the use of The invention also provides for providing support to a user of the retinal disease management system 48 (e.g., a subject, a treating physician) via online assistance and / or inbound telephone-based assistance, 6) obtaining and storing identification and treatment-related data for each of the treating physicians of the subject monitored via the retinal disease management system 48, 7) providing education to the treating physicians regarding treatment of the subject's retinal disease, 8) obtaining and storing parameters from each treating professional upon which monitoring reports and subject alerts generated by the retinal disease management system 48 are based, which monitoring reports and subject alerts are transmitted to the treating professional of each of the subjects monitored via the retinal disease management system 48, and / or 9) generating and transmitting recommended treatment parameters. In some embodiments, the recommended treatment parameters include any suitable combination of the following: a recommended date for the next visit to the clinic to evaluate and / or treat the subject's retinal disease, a recommended date for the next injection of a therapeutic compound into the subject's eye to treat the subject's retinal disease, and a recommended type of therapeutic compound (e.g., injection amount, drug combination).
[0114] In many embodiments, the retinal disease management system 48 monitors each of the subjects' compliance with an imaging schedule for the subject. The imaging schedule (e.g., requiring the subject to use the imaging device 44 daily) may be selected by the subject's treating physician. The retinal disease management system 48 may monitor the subject's compliance by comparing the receipt of the subject's OCT imaging data to the imaging schedule. When OCT imaging data is not received from the subject that complies with the imaging schedule for the subject, the retinal disease management system 48 may generate a compliance reminder 50 and transmit the compliance reminder 50 to the subject to remind the subject of the need to use the imaging device 44 in compliance with the subject's imaging schedule.
[0115] In some embodiments, the retinal disease management system 48 processes the OCT imaging data generated for each imaging session to determine how much intraretinal fluid and / or subretinal fluid is trapped within the retina of the corresponding subject. Figure 3 An example OCT-generated image of the retina with intraretinal fluid 52 is shown. Figure 4 An example OCT-generated image of the retina with subretinal fluid 54 is shown.
[0116] In many embodiments, the retinal disease management system 48 processes the OCT image data for each of the imaging sessions for each respective subject and generates a monitoring report and / or an alarm report 56 based on the OCT image data received for the subject and transmits the monitoring report and / or the alarm report 56 to the subject's treating physician. Figure 5 , Figure 6 and Figure 7 Each of the alarm reports (56a, 56b, 56c) shows an example alarm report (56a, 56b, 56c) that can be generated by the retinal disease management system 48 and transmitted to the corresponding treating physician. Each of the alarm reports (56a, 56b, 56c) includes an intraretinal fluid presence indication output (58a, 58b, 58c), a subretinal fluid presence indication output (60a, 60b, 60c), a subject name output (62a, 62b, 62c), a subject birth date output (64a, 64b, 64c), an imaging date output (66a, 66b, 66c), an imaged eye indication output (68a, 68b, 68c), and an image of the retina cross-sectional area of the detected fluid. T images (70a, 70b, 70c), plan view intraretinal fluid maps (72a, 72b, 72c) of intraretinal fluid within the imaged retina, plan view subretinal fluid maps (74a, 74b, 74c) of subretinal fluid within the imaged retina, alarm criteria (76a, 76b, 76c) for triggering the generation of an alarm report (56a, 56b, 56c), and a graphical representation (78a, 78b, 78c) showing changes in one or more tracked biomarkers indicative of the extent of retinal disease in a subject. The graphical representation (78a, 78b, 78c) may display any suitable tracked biomarker indicative of the extent of retinal disease in a subject, or any suitable combination of two or more suitable tracked biomarkers indicative of the extent of retinal disease in a subject. Figure 5In the example of FIG. 56 , graph 78a shows the average fluid thickness of both the intraretinal fluid and the subretinal fluid within the imaged retina. In the example of FIG. 56 a, graph 78a shows that after the therapeutic compound is injected into the eye, both the intraretinal fluid thickness and the subretinal fluid thickness within the imaged retina decrease, followed by a period of relatively low intraretinal fluid thickness and subretinal fluid thickness, followed by an increase in both the intraretinal fluid thickness and the subretinal fluid thickness. Figure 6 In the example of FIG. 56 , graph 78 b shows the average fluid volume of both intraretinal fluid and subretinal fluid within the imaged retina. In the example of FIG. 56 b , graph 78 b shows a period of relatively low intraretinal fluid and subretinal fluid volumes followed by an increase in intraretinal fluid volume. Figure 7 In the example of FIG. 56 , graph 78 c shows the average fluid volume of both intraretinal fluid and subretinal fluid within the imaged retina. In the alarm report 56 c , graph 78 c shows a relatively constant subretinal fluid volume, and an insignificant intraretinal fluid volume.
[0117] Figure 8A graphical representation 80 of intraretinal fluid volume values 82 and subretinal fluid volume values 84 over a date span between treatments according to an embodiment is shown. The retinal disease management system 48 can process the OCT image data of each imaging session of the subject's retina to determine a corresponding one of the intraretinal fluid volume values 82 and a corresponding one of the subretinal fluid volume values 84 using the methods described herein. The retinal disease management system 48 can be configured to process the intraretinal fluid volume values 82 and / or the subretinal fluid volume values 84 to determine a fluid regression interval (FRI) 86, a fluid presence interval (FPI) 88, a fluid absence interval (FAI) 90, and a fluid increase interval (FII) 92. The fluid regression interval (FRI) 86 is a time interval from the start of a treatment application (e.g., injection of a therapeutic compound into the subject's eye) during which retinal fluid (e.g., intraretinal fluid, subretinal fluid) is present but the volume decreases to a measurable level or below a selected minimum standard volume. The fluid presence interval (FPI) 88 is the time interval from before the treatment application to after the treatment application, during which the retinal fluid is present in a measurable amount or above a selected minimum standard volume. The fluid absence interval (FAI) 90 is the time interval between two consecutive treatment applications, during which the retinal fluid is not present in a measurable amount or below a selected minimum standard volume. The fluid increase interval (FII) 92 is the time interval before the treatment application, during which the retinal fluid is above a measurable level or a selected minimum standard volume and the volume is increasing. In some embodiments, one or more of FRI 86, FPI 88, FAI 90 and / or FII 92 are used alone and / or in combination, as input parameters for an algorithm for formulating treatment recommendations for a subject, and / or are output to treatment professionals to further quantify the state of the subject's retinal disease and / or how the subject reacts to one or more treatment applications.
[0118] Fig. 9A graph is shown of some different example rates of progression of retinal fluid accumulation that can be tracked and identified via method 10. The illustrated retinal fluid progression rates show retinal fluid progression from 0.0 nanometers to 50.0 nanometers, and include an example lower progression curve 94, an example intermediate progression curve 96, and an upper progression curve 98. For the lower progression curve 94, it took about 30 days for the detected retinal fluid volume to increase from 0.0 nanometers to 30.0 nanoliters, and about another 10 days for the retinal fluid volume to increase from 30.0 nanoliters to 50.0 nanoliters. For the intermediate progression curve 96, it took about 22 days for the detected retinal fluid volume to increase from 0.0 nanometers to 30.0 nanoliters, and about another 7.5 days for the retinal fluid volume to increase from 30.0 nanoliters to 50.0 nanoliters. For the upper progression curve 98, it took about 15 days for the detected retinal fluid volume to increase from 0.0 nanometers to 30.0 nanoliters, and about another 5 days for the retinal fluid volume to increase from 30.0 nanoliters to 50.0 nanoliters.
[0119] Fig. 9 The different example retinal fluid progression rates shown in the have different associated treatment windows due to the different retinal fluid progression rates. For example, if the criteria for generating the alarm report 56 is set at the retinal fluid volume reaching 30 nanoliters, the additional days before the retinal fluid volume reaches 50 nanoliters are different for the different illustrated progression rates as described above (i.e., only 5 days for the higher progression curve 98, compared to 10 days for the lower progression curve 94). In order to treat before the retinal fluid level exceeds the selected standard level (e.g., 50 nanoliters) to avoid damage caused by excessive retinal fluid volume, the next treatment application schedule date can be prioritized in the case of a higher retinal fluid progression rate compared to a lower retinal fluid progression rate.
[0120] In some embodiments, the criteria for generating and transmitting the alarm report 56 to the treating physician take into account differences in progression rates. For example, the criteria for triggering the generation and transmission of the alarm report 56 to the treating physician may take into account the demonstrated daily rate of retinal fluid progression between the most recent imaging of the retina and the previous day's imaging of the retina by lowering the triggered retinal fluid volume for higher rates of retinal fluid volume progression. For example, if a 10-day treatment window is desired, the lookup table may be configured and accessed so that different demonstrated retinal fluid volume progression rates each trigger the generation and transmission of the alarm report 56 to the treating physician so as to leave an expected 10-day treatment window before the planned retinal fluid volume exceeds the selected maximum pre-treatment retinal fluid volume. Assuming a maximum pre-treatment retinal fluid volume of 50 nanometers and a desired treatment window of 10 days, the retinal fluid volume increase from day 29 to day 30 of the lower retinal fluid volume progression curve 94, which is approximately 1.72 nanometers / day, can be associated with a 30.0 nanometer alarm limit that is reached on day 30, thereby triggering the generation and transmission of the alarm report 56 on day 30, leaving 10 days before the retinal fluid volume is scheduled to reach the selected maximum pre-treatment retinal fluid volume of 50 nanometers. For the intermediate retinal fluid volume progression curve 96, the retinal fluid volume increase from day 18 to day 19, which is approximately 2.02 nanometers / day, can be associated with a 23.4 nanometer alarm limit that is reached on day 19, thereby triggering the generation and transmission of the alarm report 56 on day 19, leaving 10.5 days before the retinal fluid volume is scheduled to reach the selected maximum pre-treatment retinal fluid volume of 50 nanometers. For the higher retinal fluid volume progression curve 98, the increase in retinal fluid volume from day 9 to day 10, which is approximately 2.40 nm / day, can be associated with a 15.0 nm alarm limit, which is reached on day 10, thereby triggering the generation and transmission of an alarm report 56 on day 10, leaving 10.0 days before the retinal fluid volume is scheduled to reach the selected maximum pre-treatment retinal fluid volume of 50 nm.
[0121] Fig.10A diagram showing some different types of responders to a therapeutic application that can be tracked and identified via method 10 is shown. The responder types shown include an example intermediate responder 100, an example fast responder 102, and an example slow responder 104. For the example intermediate responder 100 shown, the liquid volume was reduced from an initial 240 nanometers to 50 nanometers in about 10 days. For the example fast responder 102, the liquid volume was reduced from an initial 240 nanometers to 50 nanometers in about 7 days. In contrast, for the example slow responder 104, the liquid volume was reduced from an initial 240 nanometers to 50 nanometers in about 27 days. In some embodiments, the observed response of a particular subject to a particular treatment is classified into an appropriate response type (such as one of a fast responder, an intermediate responder, and a slow responder), and the classification of the response is provided to the treatment professional, and the recommendation is about the future treatment application for the subject based on the classification of the subject's response combined with the details of the treatment application that produced the observed response.
[0122] Fig.11 A graph showing an example non-responder 110 to a therapeutic application that can be tracked and identified via method 10 is shown. To help illustrate the differences between subjects that may occur between therapeutic applications, the graph includes an example intermediate responder 112 and a fast responder 114. If the retinas of the three illustrated responder types were imaged only in the clinic concurrently with the therapeutic application (in the illustrated example, this occurred at Day 0 and Day 30), each subject's retinal disease would exhibit the same retinal fluid volume. In contrast, by adding additional remote imaging between therapeutic applications (occurring daily in the illustrated example), the differences in response between the example non-responder 110, the example intermediate responder 112, and the fast responder 84 are observable and can form at least a partial basis for selecting an appropriate subsequent treatment for each subject's retinal disease, and particularly for the non-responder 110, selecting a different (multiple) treatment regimens given the non-response to the prior therapeutic application.
[0123] Table 1 lists example parameters related to a subject's retinal disease that may be quantified for each OCT image of the subject's retina.
[0124] The parameters in Table 1 can be used by a treating professional to track and / or formulate future treatment plans for a subject's retina. The parameters in Table 1 can be quantified for each OCT image of the subject's retina using a suitable image processing method, including but not limited to the imaging processing methods described herein.
[0125] Liquid volume determination
[0126] In many embodiments of method 10, OCT image data of each imaging session of the subject's retina is processed using a suitable image processing method to detect whether retinal fluid (e.g., intraretinal fluid volume and / or subretinal fluid volume) is present, and if so, to detect the volume(s) of the retinal fluid. For example, in some embodiments, a series of parallel OCT B-scans (where each OCT B-scan corresponds to a cross-sectional OCT image of the retina) is processed to detect whether the B-scans include any retinal fluid regions, and if so, to detect the area(s) of retinal fluid in the B-scans. The volume of retinal fluid can then be calculated based on the area of fluid in each of the series of parallel OCT B-scans and the distance between adjacent B-scans in the B-scans using Equation 1.
[0127] FV i =(FA i +FA i+1 )*0.5*DT / 2+(FA i +FA i-1 )*0.5*DT / 2(Equation 1) Among them: FA i It is a B-scan i The area of retinal fluid in FA i+1 It is a B-scan i+1 The area of retinal fluid in FA i-1 It is a B-scan i -1 is the area of retinal fluid, and DT = distance between adjacent B scans.
[0128] Fig. 12A and Fig. 12B A graph of example retinal fluid volume trajectories is shown illustrating how pre-scheduled treatments and extended visit times may expose the retina to additional deleterious fluid accumulation prior to treatment. When used in conjunction with the periodic OCT retinal imaging described herein, patient-customized fluid volume thresholds and alerts may be employed to tailor treatment timing to a specific patient's retinal disease state and its progression, thereby enabling more timely treatment relative to the activated stage of retinal disease where fluid accumulation occurs. As a result of more timely treatment, exposure of the retina to additional deleterious fluid accumulation prior to treatment may be reduced relative to pre-scheduled treatment, which may provide improved visual outcomes.
[0129] FIG. 13A to FIG. 13FA graph of an example retinal fluid volume trajectory is shown, along with the associated customized treatments applied when fluid volume thresholds and alarm indications are customized by the patient. As illustrated, the patient-customized treatment times enabled by home OCT retinal imaging can lead to improved management of very heterogeneous retinal diseases. In addition, home OCT retinal imaging can enable faster extension of retreatment intervals by delaying retreatment until an appropriate threshold for retinal fluid volume is exceeded. Home OCT retinal imaging can also provide disease status / progression data that aids in making decisions between appropriate treatments (e.g., deciding between a more expensive brand name injectable therapeutic compound and a generic injectable therapeutic compound, or deciding between a more expensive but longer duration treatment and a less expensive but shorter duration treatment).
[0130] Regular (e.g., daily) home OCT retinal imaging can be used to detect accumulation of intraretinal fluid and track the volume and distribution of intraretinal fluid over time. The volume and distribution of intraretinal fluid over time can be included in a structured input to a treatment algorithm (e.g., a machine learning algorithm) to generate treatment recommendations (e.g., time of injection, recommended therapeutic compound, recommended injection volume, etc.), treatment alerts, and / or treatment outcome predictions. The structured input to the treatment algorithm can also include treatment data (injection date and / or time, injection compound, injection volume, etc.) and / or visual acuity data.
[0131] Home OCT retinal imaging can be used to generate three-dimensional information about retinal pathology. Daily home OCT retinal imaging adds a time dimension to the three-dimensional information, creating a four-dimensional data set of retinal fluid data. Retinal fluid amount and distribution can be displayed on a retinal fluid map, such as a fluid volume thickness map. Changes in retinal fluid amount and distribution can be displayed using a sequence of fluid volume thickness maps and / or using a fluid volume change percentage map indicating changes in fluid volume and distribution between two selected dates and / or times. The determined distribution of intraretinal fluid and / or changes in intraretinal fluid amount and / or distribution over time can be displayed using any suitable method, such as any of the two-dimensional fluid distribution and / or change maps described herein.
[0132] Fig.14 and Fig.15A method 120 for managing treatment of retinal diseases via home OCT retinal imaging is illustrated. In act 122, home OCT three-dimensional imaging of the retina (e.g., a volume of the entire retina) is used to generate OCT retinal image data for each periodic imaging session of the retina at a suitable periodicity (e.g., once a day). In act 124, the OCT retinal image data for each periodic imaging session of the retina is processed to detect the presence of accumulated fluid within the retina, the distribution of accumulated fluid within the retina, and the amount of accumulated fluid within the retina. The home OCT retinal image data for each imaging session can be segmented using a suitable known algorithm (e.g., an image processing algorithm that detects fluid areas, an artificial intelligence (AI) algorithm that enables fluid localization and fluid volume quantification). In some embodiments, the processing of the home OCT retinal image data for each periodic imaging session of the retina includes: processing a penetration depth (B-scan) cross-sectional OCT image of the retina to detect fluid areas, and integrating the detected fluid areas (both in the depth direction and in the radial direction relative to the optical axis of the eye) to determine the amount and distribution of fluid within the retina. In action 126, one or more liquid distribution profiles 128 may be prepared for each of the consecutive days, wherein the profiles (e.g., color profiles, contour lines) are used to indicate the amount and distribution of fluid accumulation in the retina. The liquid distribution profiles 128 may be displayed in any suitable combination and sequence to show the amount and distribution of fluid in the retina over time. In action 130, a liquid volume trajectory graph 132 is prepared and displayed, which represents the change of a suitable parameter indicating the volume of fluid in the retina. For example, a suitable algorithm may be used to process daily home OCT retinal image data to generate a liquid volume trajectory for any suitable retinal fluid volume parameter. In action 134, the liquid volume quantification data and / or liquid positioning data are processed to generate treatment recommendations (e.g., time of injection, recommended therapeutic compound, recommended injection volume, etc.). For example, the liquid volume quantification data and liquid positioning data may be input into an AI-based algorithm to generate treatment recommendations and / or visual acuity predictions. The AI-based algorithm may be trained using liquid volume quantification data, liquid positioning data, and treatment data (injection date / time, injection volume, injection compound). In some instances, treatment data can be obtained from the patient's electronic medical record. The AI-based algorithm can be configured to classify the patient's retinal pathology and inform medical decisions on how to treat the patient's retinal pathology. As described herein, an alarm can also be generated in response to the accumulated fluid exceeding a suitable fluid threshold. The patient's electronic medical record (EMR) can be updated to include treatment recommendations and / or warnings. In action 136, the fluid volume quantification data and / or the fluid positioning data are processed to predict treatment outcomes, such as predicted improvements in visual acuity.
[0133] Fig.16 Some example retinal fluid volume trajectory segments are shown, which can be automatically identified in an embodiment. Example retinal fluid volume trajectory segments can include one or more activation segments 138, one or more treatment response segments 140, and one or more steady-state segments 142. Each activation segment 138 is characterized by an increased retinal fluid volume. Each treatment response segment 140 occurs after the implementation of treatment (e.g., injection of a therapeutic compound into the eye) and is typically characterized by a reduced retinal fluid volume produced by the treatment implementation. Each steady-state segment 142 is characterized by a retinal fluid volume that fluctuates between appropriate thresholds. Fig.17A and Fig. 17B Plots of example retinal fluid volume trajectories with automatically identified segments are shown.
[0134] The retinal fluid volume trajectory can be segmented using any suitable method. In some embodiments, mathematical / statistical tools are used to identify one or more activation segments 138 via detecting the trend of increasing retinal fluid volume, one or more steady-state segments 142 via detecting substantially stable retinal fluid volume, and one or more treatment response segments 140 via detecting the trend of decreasing retinal fluid volume. Polynomials can be fitted to the retinal fluid volume trajectory and analyzed to detect segments 138, 140, 142 so as to smooth the daily fluid volume change rate to reduce the noise level in the retinal fluid volume trajectory. The retinal fluid volume trajectory can be processed to determine the relationship between the noise level (e.g., mean square error) and the volume change level. Any suitable method (e.g., via importing from the patient's electronic medical record) can be used to automatically identify treatment events (e.g., injection of therapeutic compounds). In the absence of treatment records, treatment events can also be manually added to the patient's data set. Table 2 lists example characteristics of treatment response segments and activation segments. Table 3 defines example fluid dynamic parameters applicable to treatment segments and activation segments.
[0135] Table 2 - Fluid Dynamic Parameters - Activation and Response
[0135] Table 3 - Fluid Dynamic Parameters - Activation and Response parameter Notes Number of data points (per eye) N Liquid Volume Data Points <![CDATA[v i ]]> Central sub-area thickness data points <![CDATA[th i ]]> Central sub-area liquid data points <![CDATA[v si ]]> Number of reactivations <![CDATA[N 再激活 ]]> Number of months of research M
[0137] Any suitable combination of the retinal fluid parameters described herein can be used as an input parameter to any suitable algorithm that generates an output related to the treatment and / or management of a patient's retinal disease. For example, any suitable combination of the retinal fluid parameters described herein can be used as an input parameter to a reactivation prediction algorithm to generate a prediction of the pattern, time, and / or evolution of the future reactivation segment 138 of the patient's retinal fluid volume trajectory. Any suitable combination of the retinal fluid parameters described herein can be used as an input parameter to a treatment response prediction algorithm to generate a prediction of the pattern, time, and / or evolution of the future treatment response segment 140 of the patient's retinal fluid volume trajectory. Any suitable combination of the retinal fluid parameters described herein can be used as an input parameter to a treatment recommendation algorithm to generate a treatment recommendation for the patient (e.g., a recommended date for treatment injection, a recommended treatment compound for treatment injection, and / or a recommended volume of a treatment compound for treatment injection). Any suitable combination of the retinal fluid parameters described herein can be used as an input parameter to a feature ranking algorithm to generate a ranking of the correlation of the retinal fluid parameters with any prediction and / or recommendation described herein. Any suitable combination of the retinal fluid parameters described herein can be used as an input parameter to a retinal disease classification algorithm to generate a classification of the patient's retinal disease. The classification of the patient's retinal disease may indicate the severity of the patient's retinal disease and / or the predicted effectiveness of a treatment for the patient's retinal disease.
[0138] Any suitable method may be used to formulate the algorithms described herein. For example, machine learning (whether supervised or unsupervised) may be used to formulate the algorithms described herein. Machine learning may be used to define a training data set using a suitable number of retinal fluid volume trajectories (and in some cases, previous treatment data) to formulate a reactivation algorithm and / or a treatment response prediction algorithm. Machine learning may also be used to define a training data set using a suitable number of retinal fluid volume trajectories in combination with associated medically appropriate treatment application data to formulate a treatment recommendation algorithm, such that the treatment recommendation algorithm is configured to automatically generate medically appropriate future treatment recommendations based on the patient's retinal fluid volume trajectory and (if available) any previous treatment applications for the patient.
[0139] FIG. 18A to FIG. 24E Example retinal fluid volume trajectory graphs and associated fluid volume / distribution graphs generated using the systems and methods described herein are shown. Fig.18AAn example segmented retinal fluid volume trajectory is shown, including a first response segment and a second response segment. Fig.18B Shown in Fig.18A Retinal fluid volume trajectory of the OCT retinal images obtained during the first response segmentation. Fig.18C Shown in Fig.18A Figure 2. Retinal fluid volume trajectory of the OCT retinal images obtained during the second response segmentation. Fig.19A A graph of an example retinal fluid volume trajectory of a portion of a patient's retina is shown and includes a first activation segment, a first response segment, a second activation segment, and a second response segment. Fig.19B Shown in Fig.19A Fluid volume map of the OCT retinal image acquired during the first activated segmentation. Fig.19C Shown in Fig.19A Fluid volume map of OCT retinal images acquired during the second activation segmentation. Fig. 20A A graph showing an example retinal fluid volume trajectory for a portion of the retina of another patient is shown. Fig. 20B Shown in Fig. 20A Fluid volume map of the OCT retinal image acquired during the first activated segmentation. Fig. 20C Shown in Fig. 20A Fluid volume maps of OCT retinal images acquired during first response segmentation. Fig.20D Shown in Fig. 20A Fluid volume map of OCT retinal images acquired during the second activation segmentation. Fig.20E Shown in Fig. 20A Fluid volume maps of OCT retinal images acquired during the second response segmentation. Fig.20F Shows Fig. 20A Graph of percent fluid reduction in treatment response for the first response segment. Figure 20G Shows Fig. 20A Figure 2 shows a graph of percent fluid reduction in response to treatment for the second response segment. Fig. 20H Shows Fig. 20A Figure 3. First half-life fluid volume plot of the retinal fluid volume trajectory. Fig.20I Shows Fig. 20A Figure 2. Second half-life fluid volume plot of the retinal fluid volume trajectory. Fig.21A A graph showing an example retinal fluid volume trajectory for a portion of the retina of another patient is shown. Fig.21B Shown in Fig.21A Fluid volume map of the OCT retinal image acquired during the first activated segmentation. Fig. 21C Shown in Fig.21A Fluid volume maps of OCT retinal images acquired during first response segmentation. Fig.21DShown in Fig.21A Fluid volume map of OCT retinal images acquired during the second activation segmentation. Fig.21E Shown in Fig.21A Fluid volume maps of OCT retinal images acquired during the second response segmentation. Fig.21F Shows Fig.21A Graph of percent fluid reduction in treatment response for the first response segment. Figure 21G Shows Fig.21A Figure 2 shows a graph of percent fluid reduction in response to treatment for the second response segment. Fig.21H Shows Fig.21A Figure 3. First half-life fluid volume plot of the retinal fluid volume trajectory. Fig.21I Shows Fig.21A Figure 2. Second half-life fluid volume plot of the retinal fluid volume trajectory. Fig.22A A graph showing an example retinal fluid volume trajectory for a portion of the retina of another patient is shown. Fig. 22B Shown in Fig.22A Final fluid volume map of the OCT retinal images acquired during the first response segmentation. Fig. 22C Shows Fig.22A Graph of percent fluid reduction in treatment response for the first response segment. Fig.22D Shown in Fig.22A Final fluid volume map of the OCT retinal images acquired during the second response segmentation. Fig.22E Shows Fig.22A Figure 2 shows a graph of percent fluid reduction in response to treatment for the second response segment. Fig.22F Shown in Fig.22A Final fluid volume map of the OCT retinal image acquired during the third response segmentation. Figure 22G Shows Fig.22A Graph of percent fluid reduction in treatment response for the third response segment. Fig.23A , Fig. 23B and Fig.23C Fluid volume maps for the patient's three activation segments are shown. Fig.24A , Fig. 24B , Fig.24C , Fig.24D and Fig.24E The diagram shows activation in different locations within the patient's retina.
[0140] Fig.25 The figure shows (in Figure 2200 for a retinal disease management system 48. The GUI 200 is configured for use by a treating physician to manage treatment of a patient with a retinal disease. The GUI 200 includes a patient search and display portion 202 that includes patient search input fields 204, 206, a patient group drop-down menu 208, and a patient list table 210. The treating physician may enter patient search criteria in one of the patient search input fields 204, 206, and / or select a patient group using the patient group drop-down menu 208. The patient list table 210 displays a list of patients corresponding to the patient search criteria or the selected patient group. In the illustrated embodiment, the patient list table 210 displays a patient identification (PID), a patient clinic identification (clinic ID), a patient name, a patient date of birth, and a patient age for each patient included in the patient's list 210.
[0141] To access treatment management information for a particular patient, the treating physician may select one of the patients in the patient list 210 using any suitable method (e.g., touching a touch-sensitive screen to select a patient of interest, moving a cursor to select a patient of interest, entering a patient identification (PID), etc.). In the illustrated embodiment, the selected patient in the patient list 210 is indicated via a selection box 212 displaying the selected patient. The GUI 200 includes a selected patient portion 214 in which the patient name, patient identification (PID), patient age, patient date of birth, and patient clinic identification (clinic ID) are displayed.
[0142] For the selected patient, the GUI 200 can display any suitable number and / or combination of retinal fluid maps 216, 218, such as any of those described herein. The displayed retinal fluid maps 216, 218 can be for any selected (multiple) OCT imaging sessions of the retina of the selected patient to assist the treating physician in assessing the current state and / or progression of the retinal disease of the selected patient between two or more selected OCT imaging sessions. The displayed retinal fluid maps 216, 218 can have any suitable configuration, such as any configuration described herein. In the illustrated embodiment, each of the displayed retinal fluid maps 216, 218 includes an origin mark, a centroid mark, and a maximum fluid concentration mark. The origin mark is used to display the origin position of the initial retinal fluid in the measured retinal fluid state sequence. The centroid mark is used to mark the position of the centroid of the retinal fluid. The maximum fluid concentration is used to mark the position of the maximum retinal fluid concentration. In the illustrated configuration, the GUI 200 displays a fluid volume summary 220 that includes a total central retinal fluid volume 222 and a total peripheral retinal fluid volume 224 for the selected patient.
[0143] For the selected patient, the GUI 200 can display an activation data portion 226 that displays retinal fluid activation data for the selected patient. The displayed retinal fluid activation data can include any suitable combination of retinal fluid activation data (such as any retinal fluid activation parameters described herein). For example, in the illustrated example, the activation data portion 226 displays activation frequency, retinal fluid expansion rate, activation location, current total retinal fluid value, and an overall (e.g., composite) activation parameter. The expansion rate can indicate the current expansion rate of the retinal fluid value of the selected patient (based on changes in appropriate retinal fluid level values between recent retinal OCT images) to inform the treating physician how fast the retinal fluid of the selected patient is increasing. The overall activation parameter can be a parameter calculated based on any suitable weighted combination of the parameters in the activation data portion 226.
[0144] For the selected patient, the GUI 200 can display a response data section 228 that displays treatment response data for the selected patient. For example, in the example shown, the response data section 228 includes the duration of the selected patient's previous response, the contraction rate during the previous response, the minimum local fluid volume achieved during the previous response, the minimum total fluid volume achieved during the previous response, and an overall (e.g., composite) response parameter. The contraction rate can indicate the current contraction rate of the selected patient's retinal fluid value (based on the change in retinal fluid value between recent retinal OCT images) to inform the treating physician how quickly the selected patient's retinal fluid status improved during the response time period. The overall response parameter can be a parameter calculated based on any suitable weighted combination of the parameters in the response data section 228.
[0145] For the selected patient, the GUI 200 can display a recommended treatment 230 for treating the retinal disease of the selected patient. For example, in the example shown, the recommended treatment 230 displays the component therapeutic compounds and the corresponding concentrations of the component therapeutic compounds of the therapeutic compound for injection into the eye of the selected patient. The recommended treatment 230 includes a recommended volume of the therapeutic compound. The GUI 200 also displays a next activation time prediction, i.e., a prediction of when the next activation of the fluid accumulation will occur. The recommended treatment 230 and / or the next activation time prediction can be determined using any suitable method, such as, for example, based on retinal imaging data and associated treatment data accumulated for a suitable population of similarly situated patients.
[0146] Accordingly, the specification and drawings are to be regarded in an illustrative rather than a restrictive sense. It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the present disclosure as set forth in the claims.
[0147] Other variations are within the spirit of the present disclosure. Thus, while the disclosed technology is susceptible to various modifications and alternative constructions, certain illustrated embodiments thereof are shown in the drawings and have been described in detail above. It should be understood, however, that this is not intended to limit the present disclosure to the specific form or forms disclosed, but rather, is intended to cover all modifications, alternative constructions, and equivalents falling within the spirit and scope of the present disclosure as defined by the appended claims.
[0148] The use of the terms "a", "an" and "the" and similar designations in the context of describing the disclosed embodiments (especially in the context of the following claims) is intended to be interpreted as covering both the singular and the plural, unless otherwise specified herein or clearly contradicted by the context. The terms "include", "have", "include" and "cover" should be interpreted as open-ended terms (i.e., meaning "including, but not limited to"), unless otherwise noted. The term "connected" should be interpreted as being partially or completely contained, attached, or combined together, even if there are some intermediaries. Unless otherwise specified herein, the recording of the value range in this article is only intended to be used as a shorthand method for individually quoting each individual value falling within the range, and each individual value is incorporated into this specification as if it were recorded separately in this article. All methods described herein can be performed in any suitable order, unless otherwise specified herein or clearly contradicted by the context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the embodiments of the present disclosure, and does not constitute a limitation on the scope of the present disclosure, unless otherwise required. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.
[0149] Unless specifically stated otherwise, separator language such as "at least one of X, Y, or Z" is intended to be understood as being generally used within the context of indicating that an item, project, etc. may be X, Y, or Z, or any combination thereof (e.g., X, Y, and / or Z). Thus, such separator language is generally not intended to, and should not, imply that certain embodiments require that at least one of X, at least one of Y, or at least one of Z be present.
[0150] Preferred embodiments of the present disclosure are described herein, including the best mode known to the inventor for implementing the present disclosure. Variations of these preferred embodiments become apparent to those of ordinary skill in the art after reading the foregoing description. The inventor expects that those skilled in the art will adopt these variations as appropriate, and the inventor intends that the present disclosure be practiced in other forms other than those specifically described herein. Correspondingly, the present disclosure includes all modifications and equivalents of the subject matter described in the claims attached hereto, as permitted by applicable laws and regulations. In addition, any combination of the above-mentioned elements in all possible variations thereof is encompassed by the present disclosure, unless otherwise stated herein or clearly contradictory to the context.
[0151] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
Claims
1. A system for managing treatment of a retinal disease in an eye of a subject, the system comprising: a communication unit configured to receive optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina; at least one processor; as well as a tangible storage device storing non-transitory instructions executable by the at least one processor to cause the at least one processor to: processing the OCT image data of the retina to determine a series of measured retinal fluid level values; as well as A treatment recommendation for the subject is generated via execution of a treatment algorithm using input based on the series of measured retinal fluid level values.
2. The system according to claim 1, characterized in that The treatment algorithm is a machine learning algorithm that is trained using training data comprising multiple series of retinal fluid level values.
3. The system according to claim 2, characterized in that The training data includes therapeutic application data associated with the plurality of series of retinal fluid level values.
4. The system according to claim 1, characterized in that The treatment recommendation includes a recommended date for a therapeutic injection into the subject's eye.
5. The system according to claim 4, characterized in that The treatment recommendation includes a recommended compound for injection for the treatment.
6. The system according to claim 5, characterized in that The treatment recommendation includes a recommended volume of the recommended compound for injection for the treatment.
7. A system for predicting the progression of a retinal disease in an eye of a subject, the system comprising: a communication unit configured to receive optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina; at least one processor; as well as a tangible storage device storing non-transitory instructions executable by the at least one processor to cause the at least one processor to: processing the OCT image data of the retina to determine a series of measured retinal fluid level values; as well as A prediction of progression of the retinal disease is generated via execution of a prediction algorithm using input based on the series of measured retinal fluid level values.
8. The system according to claim 7, characterized in that The prediction algorithm is a machine learning algorithm that is trained using training data comprising a plurality of series of retinal fluid level values.
9. The system according to claim 8, characterized in that The training data includes therapeutic application data associated with the plurality of series of retinal fluid level values.
10. The system according to claim 9, characterized in that The prediction of progression of the retinal disease includes a predicted therapeutic response of the subject to a treatment for the retinal disease.
11. The system according to claim 10, characterized in that The treatment for the retinal disease comprises injecting a therapeutic compound into the eye of the subject.
12. The system according to claim 7, characterized in that The prediction of progression of the retinal disease includes a predicted progression over a series of increasing retinal fluid level values.
13. A system for classifying a retinal disease in an eye of a subject, the system comprising: a communication unit configured to receive optical coherence tomography (OCT) image data of a retina of a subject for each of a series of OCT imaging sessions of the retina; at least one processor; as well as a tangible storage device storing non-transitory instructions executable by the at least one processor to cause the at least one processor to: processing the OCT image data of the retina to determine a series of measured retinal fluid level values; as well as A classification of the retinal disease of the subject's eye is determined via execution of a classification algorithm using input based on the series of measured retinal fluid level values, wherein the classification is selected from a plurality of predetermined classifications.
14. The system of claim 13, wherein: The classification algorithm is a machine learning algorithm that is trained using training data comprising a plurality of series of retinal fluid level values.
15. The system of claim 14, wherein: The training data includes therapeutic application data associated with the plurality of series of retinal fluid level values.
16. The system of claim 13, wherein: The classification of the retinal disease of the subject's eye is indicative of the severity of the retinal disease of the subject's eye.
17. The system of claim 13, wherein: The classification of the retinal disease of the subject's eye is indicative of the effectiveness of a treatment for the retinal disease of the subject's eye.
Citation Information
Cited By
Ophthalmic prognosis visual simulation system and training method thereof
CN121983328A
